| Identification | Back Directory | [Name]
dynorphin amide (1-13), Ala(2)-(5-F-Phe)(4)- | [CAS]
111846-43-6 | [Synonyms]
Dafphedyn
dynorphin amide (1-13), Ala(2)-(5-F-Phe)(4)-
Dynorphin A (swine), 2-D-alanine-4-(2,3,4,5,6-pentafluoro-L-phenylalanine)-13-L-lysinamide-14-de-L-tryptophan-15-de-L-aspartic acid-16-de-L-asparagine-17-de-L-glutamine- (9CI) | [Molecular Formula]
C76H124F5N25O14 | [MOL File]
111846-43-6.mol | [Molecular Weight]
1706.95 |
| Hazard Information | Back Directory | [Description]
Dafphedyn, [D-Ala2, (F5) Phe4]-dynorphin 1-13-NH2 (DAFPHEDYN) is a potent analog of dynorphin 1-13. Intracerebroventricular administration of the dynorphin analog, [D-Ala2,(F5)Phe4]-dynorphin 1-13-NH2 (DAFPHEDYN) in rats produced diuresis and profound analgesia. Both effects were antagonized by central administration of naltrexone or naloxone. Intravenous administration of 10, 25, and 50 mg/kg of DAFPHEDYN failed to induce diuresis. The increased potency of DAFPHEDYN was apparent from the failure of an equal dose of the parent compound (dynorphin 1-13) to produce diuresis and the failure of [D-Ala2]-dynorphin 1-13-NH2 to produce analgesia. Radioligand binding studies indicated the DAFPHEDYN retains the same degree of kappa selectivity as the parent compound (dynorphin 1-13) though a drop in affinity occurred. DAFPHEDYN may be of significant interest because it retains the essential pharmacology of the parent compound and exhibits marked in vivo potency. | [Uses]
Dafphedyn is an analogue of Dynorphin (1-13). Dafphedyn has diuretic and profound analgesia effects that can be antagonized by centrally administered Naltrexone (HY-76711) or Naloxone (HY-17417A)[1]. | [in vivo]
Dafphedyn (5-40 μg, icv, once) induces profound analgesia in a dose-dependent manner in male Sprague-Dawley rats[1].
| [References]
[1] Walker JM, et al. [D-Ala2, (F5) Phe4]-dynorphin 1-13-NH2 (DAFPHEDYN): a potent analog of dynorphin 1-13. Peptides. 1987 Sep-Oct;8(5):811-7. DOI:10.1016/0196-9781(87)90064-7 |
|
|